 SAN DIEGO, Oct. 16, 2021 PRNewswire -- Neurocrine Biosciences, Inc. Nasdaq: NBIX today announced that it will present key information from its movement disorder treatments for Parkinsons disease and tardive dyskinesia TD at the American Neurological Association ANA 2021 Virtual Annual Meeting being held October 1719, 2021. Neurocrine Biosciences will present new post-hoc analysis of pooled data from the ONGENTYS opicapone BIPARK-1 and BIPARK-2 Phase 3 studies evaluating nighttime off episodes in people with Parkinsons disease and motor fluctuations. 